Fig. 1 · Structure
Documents & Downloads
Tusamitamab ravtansine
ADC
Tusamitamab ravtansine is an antibody-drug conjugate (ADC) designed to target tumor cells expressing CEACAM5. It consists of a humanized monoclonal antibody linked to the potent cytotoxic agent maytansinoid DM4 through a cleavable linker. This compound exhibits selective cytotoxicity towards CEACAM5-positive cancer cells, making it a valuable tool for targeted cancer therapy and research applications in oncology. With an average drug-to-antibody ratio (DAR) of 3.8, it provides effective delivery of the cytotoxic agent to enhance therapeutic efficacy.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 2254086-60-5 |
| Applications | ADC |
| Molecular Weight | 148000 (average) |
| Synonyms | SAR-408701; HuMAb2-3-SPDB-DM4 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.